CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced...
Australian medtech Navi raises $A6.8 million to commercialise breakthrough paediatric technology in the US
MELBOURNE, Australia and BOSTON, July 29, 2026 /PRNewswire/ -- Melbourne- and Boston-based medical device company Navi Medical Technologies has closed a $A6.8 million capital raise to commercialise its breakthrough paediatric vascular access...